NEW YORK, July 22, 2026, 05:04 (EDT) – Danaher (DHR) shares dropped 11% in early trading, as the company’s latest results showed its biotech segment underperformed growth forecasts, prompting a market recalibration of the stock’s valuation.
- Danaher shares ended the session at $179.01, dropping 10.99% for their largest single-day decline since June 2001.
- Quarterly revenue and adjusted earnings exceeded expectations. However, full-year core growth outlook tightened to 3%–4%.
- The forecasted adjusted earnings multiple dropped to 21.0 times from 23.8 times, using range midpoints.
U.S. cash markets remained shut when the report was filed. Shares of Danaher Corporation NYSE:DHR dropped 11% entering Wednesday’s premarket session. On Tuesday, it was the S&P 500’s poorest performer.
The drop was a recalibration of valuation rather than earnings. At Monday’s close, shares reflected prior guidance at 23.8 times adjusted earnings. After Tuesday’s session, the higher forecast was priced at roughly 21 times earnings.
| Reset metric | Before earnings | After earnings | Change |
|---|---|---|---|
| 2026 core-growth midpoint | 4.5% | 3.5% | -1.0 percentage point |
| Adjusted EPS midpoint | $8.45 | $8.525 | +0.9% |
| Danaher share price | $201.11 | $179.01 | -11.0% |
| Price/guided adjusted EPS | 23.8x | 21.0x | -2.8x |
Company guidance and closing prices are used to calculate midpoints and multiples.
The midpoint for earnings edged higher. The midpoint for core growth dropped roughly 22%. Investors gave considerably more emphasis to the latter.
An initial estimate, based on the quarter’s diluted share count, values the equity loss at about $15.6 billion. This equates to approximately 1.6 times the $9.9 billion that Masimo paid in the acquisition. However, Chief Financial Officer Matt Gugino stated that just a little over $100 million in bioprocessing revenue was pushed into 2027.
The response suggests a wider worry. Investors seem to be doubting the sustainability of growth and the reliability of forecasts, rather than just the schedule of shipments.
The quarter delivered strong results. Revenue rose 5.5% to $6.27 billion, surpassing FactSet’s forecast of $6.11 billion. Adjusted earnings stood at $1.94 per share, ahead of the roughly $1.84 expected. Core revenue advanced 3%, compared to a 0.5% increase in the previous quarter.
Biotechnology was the main area of softness. Core sales for the segment rose 2.5%, roughly 300 basis points short of analysts’ estimates. Life Sciences recorded a 5.5% increase. Diagnostics advanced by 2%, or 5% when respiratory testing was not included.
Chief Executive Rainer Blair stated, “Underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter.” As a result, orders significantly outpaced reported biotechnology growth. Danaher Corporation Investors
Analysts stayed wary. Matt Larew, an analyst at William Blair, described bioprocessing as “surprisingly soft.” Guggenheim analyst Subbu Nambi noted that focus would remain on biotechnology growth in the second half. Investor’s Business Daily
Danaher anticipates core growth of 2%–3% for the third quarter, factoring in a 2.5-point negative impact from respiratory testing. Excluding respiratory testing, growth is expected to be near 5%, with biotechnology projected to achieve mid-single-digit growth.
The company continues to anticipate total core growth in the mid-single-digit range for the fourth quarter. This outlook has gained significance. Investors are seeking confirmation that high order volumes will translate to shipments.
Danaher increased its adjusted EPS outlook to a range of $8.45–$8.60, up from $8.35–$8.55, supported by the earlier-than-expected closing of Masimo. Free cash flow grew 15.5% in the quarter, reaching $1.27 billion.
The stock finished trading at $205.01 last Thursday before falling 12.7% by Tuesday. In contrast, the S&P 500 rose 0.9% that day, indicating Danaher’s decline was mostly due to company-specific factors.
The next sector test is set for Thursday, when Thermo Fisher Scientific NYSE:TMO will issue its report before markets open on July 23. Investors will watch for its remarks on biopharma and research demand, which could indicate if Danaher’s recent softness is being felt sector-wide.
Risks: There is potential for further delays in bioprocessing shipments. Volatility in respiratory demand is possible. The Masimo integration, acquisition-related debt, and tariffs present execution and liquidity challenges.
Danaher trades at 21 times its guided adjusted earnings, making it less expensive than Monday. However, this lower valuation remains to be justified. Orders running in the mid-teens need to translate into biotechnology sales in the mid-single-digit range.
Related articles: NYSE:DHR
